GABRA3: IHC Expression in Cancer and Radioligand Target Profile
GABRA3, gamma-aminobutyric acid type A receptor subunit alpha3, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, GABRA3 staining is highest in prostate cancer (27% of samples positive). Evidence on whether GABRA3 internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is GABRA3 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze GABRA3 freeIs GABRA3 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Low IHC staining in prostate cancer, 27% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
GABRA3 IHC staining by cancer type
Protein expression of GABRA3 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Prostate Cancer | 0.12 | Low | 27% |
Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, ovarian cancer, lymphoma, breast cancer, melanoma, kidney cancer, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, pancreatic cancer, gastric cancer, testicular cancer, endometrial cancer, glioma, liver cancer.
Is GABRA3 internalized?
Uncertain. Insufficient literature found.
GABRA3 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for GABRA3 yet. Search ClinicalTrials.gov for GABRA3 trials.
GABRA3 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See GABRA3 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
GABRA3 gene essentiality (DepMap)
CRISPR knockout effect across 1250 cancer cell lines: 0.28 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related prostate cancer radioligand targets
PSMA (FOLH1) · HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · FAP · B7-H3 (CD276) · STEAP2
See all radioligand therapy targets in prostate cancer.
See how GABRA3 ranks against 15,000 targets for your indication.
Analyze GABRA3 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.